California lawmakers could soon clear a governmental logjam that has held up dozens of studies related to addiction treatment, psychedelics and other federally restricted drugs. The holdup revolves around the Research Advisory Panel of California, established decades ago to vet studies involving cannabis, hallucinogens and treatments for 'abuse of controlled substances.
Center for Cannabis and Cannabinoids, said she had submitted one study to the California panel over a year ago — one already approved by the National Institutes of Health, the Food and Drug Administration, and an institutional review board. That research will assess the health risks of cannabis for seniors and young adults ages 18 to 25, two groups whose cannabis use has been on the rise, she said.
center had submitted to the panel — one examining whether cannabis could be used as an alternative to opioids for pain relief, another on whether a psychedelic compound found in mushrooms, psilocybin, could help treat people struggling with cocaine addiction. And Cooper said she hasn't even bothered to submit three more studies, including research on the effects of high-potency cannabis.
psychologist and addiction researcher Steven Shoptaw called it 'an unequal burden on addiction research' compared with other scientific studies. The California panel has been vetting not only studies that involve federally restricted drugs, but also those assessing any kind of medication to treat addiction, said Dr. Phillip Coffin, a UC San Francisco professor of medicine who has called to eliminate the panel.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Nature - 🏆 64. / 68 Read more »
Source: mercnews - 🏆 88. / 68 Read more »